Transgene's therapeutic vaccine for cervical and anogenital cancers has failed a phase 2 trial, but an efficacy signal warrants further study, says the company. The French biotech's study of ...
Transgene and ProBioGen, a CDMO, inked a license agreement for ProBioGen’s AGE1.CR.pIX ® suspension cell line which will combine ProBioGen’s specific production technology with the ...
Given the considerable time and effort companies have invested in gene therapy, most prefer to play it safe when it comes to manufacturing. Accordingly, the large majority of recombinant adeno ...
Transgene and NEC will present promising new data from the ongoing randomized Phase I trial of the neoantigen individualized therapeutic cancer vaccine, TG4050 at SITC 2024 on November 9, 2024 ...
Figure 1: Expression of reporter gene constructs derived from the gcy-5, lim-6 and lsy-6 genes. One potential explanation for our observations is that the vector backbone may dictate the packaging ...
STRASBOURG, France and BERLIN, Germany, November 05, 2024 / Biotech Newswire / -- Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the ...
Key events and upcoming milestones TG4050: Neoantigen therapeutic cancer vaccine Transgene and NEC will present promising new data from the ongoing randomized Phase I trial of the neoantigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback